Sofinnova Partners Closes €725 Million Crossover II Fund

Sofinnova Partners has closed its second crossover fund with €725 million, equivalent to approximately $815 million. The fund will invest in late-stage life sciences companies progressing through clinical development, international expansion and commercialization.

Supporting European Life Sciences Growth

Sofinnova Crossover II will provide capital to companies that have moved beyond early scientific discovery and require funding for later clinical trials, commercial preparation and global market entry.

The firm believes Europe is producing more life sciences businesses with the science, clinical validation and leadership required to compete internationally.

Crossover investing can span private and public companies, allowing the fund to support businesses through multiple stages of development.

The strategy also gives companies access to capital during periods when public biotechnology markets or traditional financing sources may be less receptive.

Sofinnova operates from Paris, London and Milan. The firm said it will apply the disciplined investment approach used for its first crossover fund while pursuing a larger set of opportunities.

KEY QUOTES:

The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believe they should have access to investors that can support them through the critical stages of growth and commercialization.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners

We continue to see exceptional opportunities emerging across European life sciences. Many companies now have scientific strength, clinical validation, and leadership teams needed to compete on a global stage. With Sofinnova Crossover II, we are well positioned to support that next generation of leaders while maintaining the disciplined investment approach that defined our first fund.

Kinam Hong, Partner at Sofinnova Partners